Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada... [Read More]

Source: The Rheumatologist - March 31, 2020 Category: Rheumatology Authors: Reuters Staff Tags: Drug Updates clinical trials COVID-19 Regeneron Pharmaceuticals Inc. Sanofi sarilumab Source Type: research